Hepatocyte growth factor prevents tissue fibrosis, remodeling, and dysfunction in cardiomyopathic hamster hearts

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 288, Issue 5 57-5, 2005, Pages

  Nakamura, Teruya ^a   Matsumoto, Kunio ^a   Mizuno, Shinya ^a   Sawa, Yoshiki ^a   Matsuda, Hikaru ^a   Nakamura, Toshikazu ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Cardioprotection; Heart failure; Myofibroblasts; Transforming growth factor 1

Indexed keywords

ATRIAL NATRIURETIC FACTOR; COLLAGEN TYPE 1; DELTA SARCOGLYCAN; MOLECULAR MARKER; RECOMBINANT SCATTER FACTOR; SARCOGLYCAN; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ACUTE DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CARDIOMYOPATHY; CELL PROTECTION; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; DISEASE PREDISPOSITION; DISEASE SEVERITY; DOWN REGULATION; HEART DILATATION; HEART FAILURE; HEART FUNCTION; HEART INJURY; HEART MUSCLE FIBROSIS; MALE; MYOFIBROBLAST; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SYRIAN HAMSTER;

ANGIOTENSIN II; ANIMALS; CARDIOMYOPATHY, DILATED; CARDIOMYOPATHY, HYPERTROPHIC; CHO CELLS; CRICETINAE; FIBROSIS; GENE EXPRESSION; HEPATOCYTE GROWTH FACTOR; HUMANS; MALE; MESOCRICETUS; MYOCYTES, CARDIAC; PROTO-ONCOGENE PROTEINS C-MET; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; VASOCONSTRICTOR AGENTS; VENTRICULAR REMODELING;

EID: 18044387835     PISSN: 03636135     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpheart.01239.2003     Document Type: Article

References (49)

1. Ahmet I, Sawa Y, Iwata X, and Matsuda H. Gene transfection of hepatocyte growth factor attenuates cardiac remodeling in the canine heart: a novel gene therapy for cardiomyopathy. Thorac Cardiovasc Surg 124: 957-963, 2002.
2. Aoki M, Morishita R, Taniyama Y, Kida I, Moriguchi A, Matsumoto K, Nakamura T, Kaneda Y, Higaki J, and Ogihara T. Angiogenesis induced by hepatocyte growth factor in non-infarcted myocardium and infarcted myocardium: up-regulation of essential transcription factor for angiogenesis, ets. Gene Ther 7: 417-427, 2000.
3. Balkovetz DF and Lipschutz JH. Hepatocyte growth factor and the kidney: it is not just for the liver. Int Rev Cytol 186: 225-260, 1999.
4. Bessho K, Mizuno S, Matsumoto K, and Nakamura T. Counteractive effects of HGF on PDGF-induced mesangial cell proliferation in a rat model of glomerulonephritis. Am J Physiol Renal Physiol 284: F1171-F1180, 2003.
5. Border WA and Nohle NA. Transforming growth factor-beta in tissue fibrosis. N Engl J Med 331: 1286-1292, 1994.
6. Bronzwaer JG, Heymes C, Visser CA, and Paulus WJ. Myocardial fibrosis blunts nitric oxide synthase-related preload reserve in human dilated cardiomyopathy. Am J Physiol Heart Circ Physiol 284: H10-H16, 2003.
7. Bueno OF, De-Windt LJ, Tymitz KM, Witt SA, Kimball TR, Klevitsky R, Hewett TE, Jones SP, Lefer DJ, Peng CF, Kitsis RN, and Molkentin JD. The MEK1-ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice. EMBO J 19: 6341-6350, 2000.
8. Bussolino F, Di Renzo MF, Ziche M, Bocchietto E, Olivero M, Naldini L, Gaudino G, Tamagnone L, Coffer A, and Comoglio PM. Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J Cell Biol 119: 629-641, 1992.
9. Campbell SE and Katwa LC. Angiotensin II stimulated expression of transforming growth factor-β1 in cardiac fibroblasts and myofibroblasts. J Mol Cell Cardiol 29: 1947-1958, 1997.
10. Cartwright JE, Tse WK, and Whitley GS. Hepatocyte growth factor induced human trophoblast motility involves phosphatidylinositol-3-kinase, mitogen-activated protein kinase, and inducible nitric oxide synthase. Exp Cell Res 279: 219-226, 2002.
11. Chien KR. Genomic circuits and the integrative biology of cardiac diseases. Nature 407: 227-232, 2000.
12. Chung MP, Monick MM, Hamzeh NY, Butler NS, Powers LS, and Hunninghake GW. Role of repeated lung injury and genetic background in bleomycin-induced fibrosis. Am J Respir Cell Mol Biol 29: 375-380, 2003.
13. Harrison P, Bradley L, and Bomford A. Mechanism of regulation of HGF/SF gene expression in fibroblasts by TGF-β1. Biochem Biophys Res Commun 271: 203-211, 2000.
14. Hein S, Arnon E, Kostin S, Schonburg M, Elsasser A, Polyakova V, Bauer EP, Klovekorn WP, and Schaper J. Progression from compensated hypertrophy to failure in the pressure-overloaded human heart: structural deterioration and compensatory mechanisms. Circulation 107: 984-991, 2003.
15. Heymes C, Vanderheyden M, Bronzwaer JG, Shah AM, and Paulus WJ. Endomyocardial nitric oxide synthase and left ventricular preload reserve in dilated cardiomyopathy. Circulation 99: 3009-3016, 1999.
16. Hunter JJ and Chien KR. Signaling pathways for cardiac hypertrophy and failure. N Engl J Med 341: 1276-1283, 1999.
17. Kim HW, Matsumoto K, Bessho K, and Nakamura T. Growth inhibition and apoptosis in in liver myofibroblasts promoted by hepatocyte growth factor leads to resolution from liver cirrhosis. Am J Pathol. In press.
18. Kim NN, Villarreal FJ, Printz MP, Lee AA, and Dillmann WH. Trophic effects of angiotensin II on neonatal rat cardiac myocytes are mediated by cardiac fibroblasts. Am J Physiol Endocrinol Metab 269: E426-E437, 1995.
19. Lee AA, Dillmann WH, McCulloch AD, and Villarreal FJ. Angiotensin II stimulates the autocrine production of transforming growth factor-β1 in adult rat cardiac fibroblasts. J Mol Cell Cardiol 27: 2347-2357, 1995.
20. Li YY, Feng YQ, Kadokami T, McTiernan CF, Draviam R, Watkins SC, and Feldman. Myocardial extracellular matrix remodeling in transgenic mice overexpressing tumor necrosis factor α can be modulated by anti-tumor necrosis factor α therapy. Proc Natl Acad Sci USA 97: 12746-12751, 2000.
21. MacKenna D, Summerour SR, and Villarreal FJ. Role of mechanical factors in modulating cardiac fibroblast function and extracellular matrix synthesis. Cardiovasc Res 46: 257-263, 2000.
22. Maejima Y, Ueba H, Kuroki M, Yasu T, Hashimoto S, Nabata A, Kobayashi N, Ikeda N, Saito M, and Kawakami M. Src family kinases and nitric oxide production are required for hepatocyte growth factor-stimulated endothelial cell growth. Atherosclerosis 167: 89-95, 2003.
23. Matsuda Y, Matsumoto K, Ichida T, and Nakamura T. Hepatocyte growth factor suppresses the onset of liver cirrhosis and abrogates lethal hepatic dysfunction in rats. J Biochem 118: 643-649, 1995.
24. Matsumoto K and Nakamura T. Hepatocyte growth factor: renotropic role and potential therapeutics for renal diseases. Kidney Int 59: 2023-2038, 2001.
25. Matsumoto K, Tajima H, Okazaki H, and Nakamura T. Negative regulation of hepatocyte growth factor gene expression in human lung fibroblasts and leukemic cells by transforming growth factor-β1 and glucocorticoids. J Biol Chem 267: 24917-24920, 1992.
26. Mizuno S, Kurosawa T, Matsumoto K, Mizuno-Horikawa Y, Okamoto M, and Nakamura T. Hepatocyte growth factor prevents renal fibrosis and dysfunction in a mouse model of chronic renal disease. J Clin Invest 101: 1827-1834, 1998.
27. Mizuno S, Matsumoto K, Li MY, and Nakamura T. HGF reduces advancing lung fibrosis in mice: a potential role for MMP-dependent myofibroblast apoptosis. FASEB J 19: 580-582, 2005.
28. Nakamura F, Nagano M, Kobayashi R, Higaki J, Mikami H, Kawaguchi N, Onishi S, and Ogihara T. Chronic administration of angiotensin II receptor antagonist, TCV-116, in cardiomyopathic hamsters. Am J Physiol Heart Circ Physiol 267: H2297-H2304, 1994.
29. Nakamura T, Mizuno S, Matsumoto K, Sawa Y, Matsuda H, and Nakamura T. Myocardial protection from ischemia/reperfusion injury by endogenous and exogenous HGF. J Clin Invest 106: 1511-1519, 2000.
30. Nakamura T, Nawa K, and Ichihara A. Partial purification and characterization of hepatocyte growth factor from serum of hepatectomized rats. Biochem Biophys Res Commun 122: 1450-1459, 1984.
31. Nakamura T, Nishizawa T, Hagiya M, Seki T, Shimonishi M, Sugimura A, Tashiro K, and Shimizu S. Molecular cloning and expression of human hepatocyte growth factor. Nature 342: 440-443, 1989.
32. Ozaki I, Zhao G, Mizuta T, Ogawa Y, Kara T, Kajihara S, Hisatomi A, Sakai T, and Yamamoto. Hepatocyte growth factor induces collagenase (matrix metalloproteinase-1) via the transcription factor Ets-1 in human hepatic stellate cell line. J Hepatol 36: 169-178, 2002.
33. Paquette F, Jasmin G, and Dumont L. Cardioprotective efficacy of verapamil and mibefradil in young UM-X7.1 cardiomyopathic hamsters. Cardiovasc Drugs Ther 13: 525-530, 1999.
34. Purdie KJ, Whitley GS, Johnstone AP, and Cartwright JE. Hepatocyte growth factor-induced endothelial cell motility is mediated by the upregulation of inducible nitric oxide synthase expression. Cardiovasc Res 54: 659-668, 2002.
35. Sakamoto A, Ono K, Abe M, Jasmin G, Eki T, Murakami Y, Masaki T, Toyo-oka T, and Hanaoka F. Both hypertrophic and dilated cardiomyopathies are caused by mutation of the same gene, δ-sarcoglycan, in hamster: an animal model of disrupted dystrophin-associated glycoprotein complex. Proc Natl Acad Sci USA 94: 13873-13878, 1997.
36. Schultz JJ, Witt SA, Glascock BJ, Nieman ML, Reiser PJ, Nix SL, Kimball TR, and Doetschman T. Transforming growth factor-β1 mediates the hypertrophic cardiomyocyte growth induced by angiotensin II. J Clin Invest 109: 787-796, 2002.
37. Seki T, Ihara I, Sugimura A, Shimonishi M, Nishizawa T, Asami O, Hagiya M, Nakamura T, and Shimizu S. Isolation and expression of cDNA for different forms of hepatocyte growth factor from human leukocyte. Biochem Biophys Res Commun 172: 321-327, 1990.
38. Swynghedauw B. Molecular mechanisms of myocardial remodeling. Physiol Rev 79: 215-262, 1999.
39. Takemoto M, Egashira K, Usui M, Numaguchi K, Tomita H, Tsutsui H, Shimokawa H, Sueishi K, and Takeshita A. Important role of tissue angiotensin-converting enzyme activity in the pathogenesis of coronary vascular and myocardial structural changes induced by long-term blockade of nitric oxide synthesis in rats. J Clin Invest 99: 278-287, 1997.
40. Taniyama Y, Morishita R, Aoki M, Hiraoka K, Yamasaki K, Hashiya N, Matsumoto K, Nakamura T, Kaneda Y, and Ogihara T. Angiogenesis and antifibrotic action by hepatocyte growth factor in cardiomyopathy. Hypertension 40: 47-53, 2002.
41. Taniyama Y, Morishita R, Nakagami H, Moriguchi A, Sakonjo H, Kim S, Matsumoto K, Nakamura T, Higaki J, and Ogihara T. Potential contribution of a novel antifibrotic factor, hepatocyte growth factor, to prevention of myocardial fibrosis by angiotensin II blockade in cardiomyopathic hamsters. Circulation 102: 246-252, 2002.
42. Tomita H, Egashira K, Ohara Y, Takemoto M, Koyanagi M, Katoh M, Yamamoto H, Tamaki K, Shimokawa H, and Takeshita A. Early induction of transforming growth factor-β via angiotensin II type 1 receptors contributes to cardiac fibrosis induced by long-term blockade of nitric oxide synthesis in rats. Hypertension 32: 273-279, 1998.
43. Tomita N, Morishita R, Taniyama Y, Koike H, Aoki M, Shimizu H, Matsumoto K, Nakamura T, Kaneda Y, and Ogihara T. Angiogenic property of hepatocyte growth factor is dependent on upregulation of essential transcription factor for angiogenesis, ets-1. Circulation 107: 1411-1417, 2003.
44. Ueki T, Kaneda Y, Tsutsui H, Nakanishi K, Sawa Y, Morishita R, Matsumoto K, Nakamura T, Takahashi H, Okamoto E, and Fujimoto J. Hepatocyte growth factor gene therapy of liver cirrhosis in rats. Nat Med 5: 226-230, 1999.
45. Van-Belle E, Witzenbichler B, Chen D, Silver M, Chang L, Schwall R, and Isner JM. Potentiated angiogenic effect of scatter factor/hepatocyte growth factor via induction of vascular endothelial growth factor: the case for paracrine amplification of angiogenesis. Circulation 97: 381-390, 1998.
46. Villarreal FJ and Dillmann WH. Cardiac hypertrophy-induced changes in mRNA levels for TGF-β1, fibronectin, and collagen. Am J Physiol Heart Circ Physiol 262: H1861-H1866, 1992.
47. Watanabe M, Kawaguchi H, Onozuka H, Mikami T, Urasawa K, Okamoto H, Watanabe S, Abe K, and Kitabatake A. Chronic effects of enalapril and amlodipine on cardiac remodeling in cardiomyopathic hamster hearts. J Cardiovasc Pharmacol 32: 248-259, 1998.
48. Yaekashiwa M, Nakayama S, Ohnuma K, Sakai T, Abe T, Satoh K, Matsumoto K, Nakamura T, Takahashi T, and Nukiwa T. Simultaneous or delayed administration of hepatocyte growth factor equally represses the fibrotic changes in murine lung injury induced by bleomycin. A morphologic study. Am J Respir Crit Care Med 156: 1937-1944, 1997.
49. Yang R, Bunting S, Ko A, Schwall R, and Jin H. Hemodynamic effects of scatter factor in conscious rats. J Cardiovasc Pharm 30: 294-301, 1997.